DEB KIENTOP
Pulaski,WI
Summary
Performance-driven Executive with over 25 years of experience in biotech and global CRO aligning systems with business requirements, policies and regulatory requirements. Passionate about applying excellent organization and communication skills to build and lead teams. Results-oriented and well-versed in interfacing and consulting on business processes to drive results based on sound overall business judgment.
Overview
26
26
years of professional experience
1
1
Certification
Work History
VP, CLINICAL OPERATIONS
DEKA BIOSCIENCES
09.2022 - Current
- Establish clinical operations within biotech organization.
- Support IND submission and regulatory agency communications.
- Business line reporting to Board of Directors.
- Partner with Finance, HR, R&D and C-Suite to build and execute on corporate strategy.
- Achieved first clinical site activated within 4 weeks of FDA clearance to proceed letter.
- Implemented standard operating procedures and educated staff on changes.
SVP, ONCOLOGY STRATEGY AND INNOVATION
ERGOMED, PLC
09.2021 - 08.2022
- Established global therapeutic strategy within CRO business
- Lead customer relationship development and new business strategy for all Oncology pharma/biotech customers- US, EU and APAC
- Increased new business by 50% over previous year.
- Supported commercial efforts through proposals and budgets, marketing content development and customer engagement
- Served as executive level oversight with 10 biotech and pharmaceutical customers.
- Partnered with Chief Information Officer on development and execution of CRO technology strategy.
- Supported engagement with patient advocacy organizations.
- Improved business process flows and productivity.
- Collaborated with cross-functional teams to establish successful execution of projects and campaigns.
VP, THERAPEUTIC STRATEGY
SYNTERACT
02.2020 - 07.2021
- Established strategy for Oncology Development Center in global CRO
- Provided strategic guidance for oncology proposals and bid defenses meetings
- Conducted 4 webinars to support new business.
- Achieved 300% increase in Net New Business for oncology
- Developed and launched oncology training certification program.
- Established and maintained relationships with key stakeholders.
SVP, LIFE SCIENCES
INTELIQUET
10.2018 - 01.2020
- Established strategy for life science and CRO business including data, technology, and services.
- Enhanced company performance by implementing new strategies and streamlining operations- revenue increase of 50% year over year.
- Business line reporting to Board of Directors.
- Led clinical trial engagement with sponsors, CROs and research sites, enabling clinical trial matching and screening efforts
- Led virtual team of project management, data science and delivery experts to execute on strategy
- Collaborated with data science and technology teams to develop new products.
SR. DIRECTOR, ONCOLOGY STRATEGY
ICON PLC
02.2014 - 09.2018
- Responsible for development and leadership of Global Oncology Strategy and Site Relationships team
- Increased yearly new business by over $300 million in 4 years.
- Supported development of operational strategy for oncology proposals and bid defense meetings
- Established Early Phase Oncology Site Network
- Liaised with oncology investigators and patient advocacy organizations.
SR. DIRECTOR ONCOLOGY STRATEGY
IQVIA (QUINTILES)
04.2010 - 02.2014
- Managed global team of oncology therapeutic strategy leads
- Led initiatives to showcase oncology expertise through publications, white papers, and KOL interactions.
- Revamped operational plans to refocus staff and align processes with business objectives.
- Monitored and coordinated workflows to optimize resources.
PRESIDENT
MSL360, LLC
06.2008 - 04.2010
- Founding partner of medical affairs consulting company focused on assisting pharmaceutical and medical device companies in developing medical affairs teams.
SR. DIRECTOR, ONCOLOGY MSL TEAM
MGI PHARMA
09.2002 - 06.2008
- Launched Medical Science Liaison function within MGI Pharma, including development of SOPs, training, and team strategy
- Managed field based MSL team responsible for launch of multiple oncology therapeutic and supportive care treatments.
DIRECTOR, ONCOLOGY MSL TEAM
MedImmune
07.1998 - 08.2002
- Managed field based MSL team and key accounts including MD Anderson, Northwestern, University, Mayo Clinic, University of Wisconsin, and Washington University
- Led investigator-initiated research program including oversight of $500k budget.
Education
CERTIFICATE- INTERNATIONAL BUSINESS -
UNIV COLLEGE DUBLIN
Dublin, Ireland02.2016
MBA - STRATEGY AND LEADERSHIP
UNIVERSITY oF WISCONSIN
OSHKOSH05.1998
Bachelor of Science - PHARMACOLOGY AND TOXICOLOGY
University of Wisconsin - Madison
Madison, WI05.1992
Skills
- Strategic Planning
- Budget Oversight
- Operational Efficiency
- Clinical Development
- Technology Evaluation and Implementation
- Team Leadership
- Coaching and Mentoring
Publications
Moser, E., Kientop, D. Et al. DEKA-1 a dose finding phase 1 trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy. Annals of Oncology 2023 34:2_supp, S496
From Technology to AI: Navigating the Path Towards Decentralized Trials in Oncology, Ergomed Webinar, November 2021.
Kientop, D. Early Phase Oncology Trials: Aligning for Operational Success. OCT UK and Ireland, June 2021. Kientop, D. Rare Cancers: Special Considerations for Complex Clinical Studies. XTalks Webinar, November 2020.
Miller, J., Kientop, D. Et al. A novel approach to support community oncology practices in building a clinical research program. Journal of Clinical Oncology 2019 37:15_suppl, e18087
Hadley, D., Edenfield, WJ, and Kientop, D. Moving away from the boilerplate: Real- world evidence for clinical trial laboratory criteria. Journal of Clinical Oncology 2019 37:15_suppl, e14581
Kientop, D. (2018) Knowledge is Powerful: The information you need when fighting cancer. Pulaski, WI: Self-published.
Kientop, D. (2010) Incorporating Medical Science Liaisons into Key Account Strategy. Journal of Medical Marketing, 10(1): 45-51.
Rosenthal, A. Maruca, B., and Kientop, D. KOL Program Development 101- A Primer for Small and MidSized Pharmaceutical, Medical Device and Biotech Companies. CBI's 6th Annual Defining Appropriate and Effective Interactions with Thought Leaders and Key Opinion Leaders, November 9, 2009.
Certification
Board Certified Patient Advocate (BCPA)
Timeline
VP, CLINICAL OPERATIONS
DEKA BIOSCIENCES
09.2022 - Current
SVP, ONCOLOGY STRATEGY AND INNOVATION
ERGOMED, PLC
09.2021 - 08.2022
VP, THERAPEUTIC STRATEGY
SYNTERACT
02.2020 - 07.2021
SVP, LIFE SCIENCES
INTELIQUET
10.2018 - 01.2020
SR. DIRECTOR, ONCOLOGY STRATEGY
ICON PLC
02.2014 - 09.2018
SR. DIRECTOR ONCOLOGY STRATEGY
IQVIA (QUINTILES)
04.2010 - 02.2014
PRESIDENT
MSL360, LLC
06.2008 - 04.2010
SR. DIRECTOR, ONCOLOGY MSL TEAM
MGI PHARMA
09.2002 - 06.2008
DIRECTOR, ONCOLOGY MSL TEAM
MedImmune
07.1998 - 08.2002
CERTIFICATE- INTERNATIONAL BUSINESS -
UNIV COLLEGE DUBLIN
MBA - STRATEGY AND LEADERSHIP
UNIVERSITY oF WISCONSIN
Bachelor of Science - PHARMACOLOGY AND TOXICOLOGY
University of Wisconsin - Madison
Similar Profiles
Kaylee CherryKaylee Cherry
Lash Artist at Deka LashLash Artist at Deka Lash
Olivince VixammarOlivince Vixammar
Warehouse Worker at Deka GroupWarehouse Worker at Deka Group
Reese GroganReese Grogan
Esthetician at Deka LashEsthetician at Deka Lash